The Study Of Soluble Nogo-B In Parkinson’s Disease Patients And Its Correlation With Motor Symptoms

Objective:Parkinson’s Disease(PD)is the second most common neurodegenerative Disease after Alzheimer’s Disease in the world,affecting more than 1% of people over the age of 65.However,diagnosis of Parkinson’s disease still depends on clinical features.Therefore,early diagnosis of PD requires sensitive and convenient biomarkers.Recently,neurite outgrowth inhibitor-B(Nogo-B)receptor has been reported as a novel candidate gene of PD.Soluble Nogo-B(s Nogo-B)can be secreted into serum and cerebrospinal fluid.Nogo-B receptor need to combine with soluble Nogo-B to exert its physiological function.However,little is known about the relationship between serum and cerebrospinal fluid soluble Nogo-B and PD.The purpose of this study was to investigate the serum and cerebrospinal fluid levels of s Nogo-B in PD patients,and to determine the correlation between serum s Nogo-B and clinical manifestations and whether serum s Nogo-B levels alone or in combination with serum α-synuclein(α-Syn)can be used to assist in the diagnosis of PD.Methods:Serum and cerebrospinal fluid of 53 PD patients and 49 healthy controls were collected from patients who attended the First Affiliated Hospital of Guangxi Medical University and the First Affiliated Hospital of Guangzhou Medical University.Clinical manifestations of PD patients were evaluated by UPDRS-III score(Unified Parkinson’s Disease Rating Scale III),H&Y(Hoehn & Yahr)stage,and NMSS(Non-motor Symptoms Scale)score.Serum and cerebrospinal fluid levels of s Nogo-B and α-Syn were determined using ELISA Kit and their relationship with clinical variables was also calculated.Results:Serum s Nogo-B level is significantly lower in PD group than that in healthy controls(p< 0.0001)and is negatively correlated with UPDRS-III score(p =0.049),H&Y stage(p = 0.0108)as well as serum α-Syn level(p = 0.0001).There is no difference in cerebrospinal fluid s Nogo-B level between PD patients and healthy controls.Area under the curve(AUC)of serum s Nogo-B in differentiating patients with PD from controls was 0.8010 while AUC of serum α-Syn was 0.930.Combining serum s Nogo-B and α-Syn in differentiating patients with PD from HC presented higher discriminatory potential(AUC = 0.9534).Conclusion:1.Level of serum s Nogo-B in PD patients was lower than that in normal subjects,and was correlated with motor symptoms and disease progression.2.Serum s Nogo-B may be a promising biomarker for early diagnosis of PD.3.The combination of serum s Nogo-B and serum α-Syn is helpful for the early diagnosis of PD.